{"article_id": "PBH_q1_2022.txt", "article": ["first , and most importantly , our base business continues to perform well with strong 5 % growth across the base portfolio .", "we estimate this accounted for approximately $ 25 million of the q1 sales increase over the prior year .", "meanwhile , our financial profile has remained solid throughout the change in consumer purchasing patterns , and we generated record earnings per share of $ 1.14 and free cash flow of approximately $ 68 million in q1 .", "combined , these brands represent about 20 % of our revenues .", "when combined with our existing eye care business , we now have a $ 100 million - plus franchise that addresses a range of consumer ailments across the $ 1 billion category .", "a brand we 've owned since our ipo over 15 years ago , clear eyes is an example of how we think about long - term brand - building .", "today , we have over 11 different solutions for consumers solving eye redness .", "q1 revenue of $ 269.2 million increased 17.3 % and 15.6 % on an organic basis versus the prior year , the latter excluding the effect of foreign currency .", "north america revenues were up about 15 % .", "international otc increased approximately 30 % in q1 after excluding the effects of foreign currency .", "ebitda increased in q1 , approximately 13 % while ebitda margin remained consistent with our long - term expectations in the mid-30s .", "diluted earnings per share for the quarter was a record $ 1.14 per share , up over 30 % versus the prior year driven by both the higher sales discussed and lower interest expense .", "q1 fiscal ' 22 revenues increased 17 % versus the prior year .", "our strong and diverse portfolio experienced approximately 5 % baseline growth driven by the favorable year ago comparison and our long - term brand - building efforts .", "in addition , we experienced a sharp rebound in certain covid - impacted categories , adding an estimated $ 25 million to our q1 revenue performance .", "total company gross margin of 59.1 % in the first quarter increased 70 basis points versus last year 's gross margin of 58.4 % .", "we continue to anticipate a gross margin of about 58 % for fiscal ' 22 .", "advertising and marketing came in at 14.7 % for the first fiscal quarter .", "following the abnormally low rate of spend in q1 of last year due to covid - 19 shelter - in - place restrictions , a&m returned to normalized levels of spend of approximately 14 % to 16 % .", "for fiscal ' 22 , we still anticipate an approximate 15 % a&m rate as a percentage of sales .", "and for q2 , we anticipate a&m of closer to 14 % .", "g&a expenses were just over 8 % of sales in q1 .", "for the full year fiscal ' 22 , we still anticipate g&a expenses to approximate just over 9 % of sales .", "lastly , record diluted earnings per share of $ 1.14 grew 32.5 % over the prior year .", "looking forward , we now anticipate interest for the full year to approximate $ 63 million , reflecting the recent financing completed in conjunction with the theratears acquisition .", "in q1 , we generated $ 67.8 million in free cash flow , down versus the prior year due entirely to the timing of working capital .", "at june 30 , our net debt was approximately $ 1.4 billion , inclusive of the cash we built ahead of the anticipated acquisition closing on july 1 .", "following the acquisition of akorn , our net debt at july one was approximately $ 1.6 billion .", "our covenant - defined leverage ratio was 4.3 times at the closing of the transaction , and we anticipate leverage of approximately four times by year - end fiscal ' 22 .", "for the full year fiscal ' 22 , we now anticipate revenues of $ 1.045 billion or more , which includes an organic revenue growth expectation of about 6 % and the revenue from the acquisition of the akorn consumer health .", "for the second quarter , we anticipate revenues of $ 260 million or more .", "this revenue outlook assumes a few key factors : one , that the travel - impacted portion of our business will continue at the recovered levels for the remainder of the year ; two , we still anticipate flat sales to prior year in the cough and cold and head lice areas of our business ; and three , the acquisition of the akorn portfolio discussed today should contribute approximately $ 40 million to the fiscal year net sales .", "we anticipate adjusted earnings per share of $ 3.90 or more for fiscal ' 22 .", "for q2 , adjusted earnings per share is expected to be $ 0.95 or more .", "these attributes translate into strong free cash flow as well , where we anticipate adjusted free cash flow of $ 245 million or more for the year ."], "summary_gold": "q1 earnings per share $ 1.14 .<q>q1 revenue $ 269.2 million versus refinitiv ibes estimate of $ 232.4 million .<q>raising full - year fiscal 2022 outlook .<q>sees 2022 adjusted earnings per share $ 3.90 or more .", "summary_pred": "total company gross margin of 59.1 % in the first quarter increased 70 basis points versus last year 's gross margin of 58.4 % .<q>for the full year fiscal ' 22 , we still anticipate g&a expenses to approximate just over 9 % of sales .<q>following the acquisition of akorn , our net debt at july one was approximately $ 1.6 billion .<q>for q2 , adjusted earnings per share is expected to be $ 0.95 or more .<q>a brand we 've owned since our ipo over 15 years ago , clear eyes is an example of how we think about long - term brand - building .<q>when combined with our existing eye care business , we now have a $ 100 million - plus franchise that addresses a range of consumer ailments across the $ 1 billion category .<q>in addition , we experienced a sharp rebound in certain covid - impacted categories , adding an estimated $ 25 million to our q1 revenue performance .<q>advertising and marketing came in at 14.7 % for the first fiscal quarter .<q>today , we have over 11 different solutions for consumers solving eye redness .<q>following the abnormally low rate of spend in q1 of last year due to covid - 19 shelter - in - place restrictions , a&m returned to normalized levels of spend of approximately 14 % to 16 % .<q>these attributes translate into strong free cash flow as well , where we anticipate adjusted free cash flow of $ 245 million or more for the year .<q>q1 revenue of $ 269.2 million increased 17.3 % and 15.6 % on an organic basis versus the prior year , the latter excluding the effect of foreign currency .<q>combined , these brands represent about 20 % of our revenues .<q>north america revenues were up about 15 % .<q>first , and most importantly , our base business continues to perform well with strong 5 % growth across the base portfolio .", "len_article": 35, "len_summary_gold": 4, "len_summary_pred": 15, "len_sent_scores": 35}